Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lutetium 177Lu Vipivotide Tetraxetan→

Lutetium 177Lu Vipivotide Tetraxetan Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1703749-62-5
Molecular formula
C49H68[177Lu]N9O16
Molecular weight
1216.1 g/mol
Drug class
Therapeutic radiopharmaceuticalprostate-specific membrane antigen (PSMA)-targeted radioligand therapy
Mechanism of action
A small-molecule ligand binds with high affinity to PSMA on prostate cancer cells and delivers beta-minus radiation from lutetium-177. The emitted radiation induces DNA damage in targeted and nearby cells, potentially leading to cell death.
Indications / reported uses
  • Treatment of adults with PSMA-positive metastatic prostate cancer under the applicable product label; patient selection and approved treatment setting depend on prior androgen-receptor pathway therapy and taxane exposure.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a · https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto · https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lutetium 177Lu Vipivotide Tetraxetan Environmental Risk Assessment (ERA) (the Lutetium 177Lu Vipivotide Tetraxetan ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.